The biopharma buffer market set for strong growth over next decade
Biopharma Buffer Market |
Market Overview:
The biopharma buffer market is estimated to be valued at US$ 3.44 billion in 2022 and is expected to exhibit a CAGR of 7.1% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights. Buffers play a key role in stabilizing the pH level of solutions used for manufacturing biopharmaceutical products. They help maintain an optimal environment for cell growth and protein expression.
Market Dynamics:
One of the key drivers fueling growth in the biopharma buffer market is rising demand for monoclonal antibodies and recombinant proteins. Buffers are critical to the manufacturing processes of these complex biomolecules. They help control pH level during cell cultivation, purification, storage and transportation of finished biologics. Growing prevalence of chronic diseases is also propelling the development of novel biologics, thus driving buffer consumption. In addition, increasing outsourcing of bioprocessing activities to contract manufacturing organizations is positively impacting the market. This is due to large-scale production of biologics requiring higher buffer volumes.
Market key trends:
The biopharma buffer market has been witnessing rising demand for screening buffers and process development buffers in recent years. Screening buffers help in evaluating the pH stability of drug molecules during drug formulation development. Process development buffers assist in optimizing downstream purification steps such as filtration, centrifugation and chromatography during bioprocessing. They provide optimal conditions to produce high yields of high-purity biopharmaceutical products. Manufacturers have been innovating new screening and process development buffers to enhance drug stability and purity.
SWOT Analysis
Strengths: Wide range of applications in biologics production, drug discovery and stability testing.
Weaknesses: Higher costs compared to traditional chemical-based buffers.
Opportunities: Growth in demand for biologics and monoclonal antibodies drives the need for advanced buffers.
Threats: Stringent regulatory guidelines regarding buffer selection and validation.
Key Takeaways
Market size: The Global Biopharma Buffer Market Size was valued at US$ 3.44 billion in 2022. The market is expected to witness high growth, exhibiting a CAGR of 7.1% over the forecast period 2023-2030, due to increasing R&D investment in biopharmaceuticals.
Regional analysis: North America dominates the global market currently due to presence of leading biopharma players and availability of advanced healthcare facilities. Asia Pacific is expected to be the fastest growing market during the forecast period with double digit CAGR owing to increasing biologics production in China, India and South Korea.
Key players: Key players operating in the biopharma buffer market are Merck KGaA, Thermo Fisher Scientific Inc., Avantor, Inc., Lonza Group Ltd., Bio-Rad Laboratories, Inc., Sartorius AG, Corning Inc., Becton, Dickinson and Company, GE Healthcare, Promega Corporation. These players are focusing on new product launches to consolidate their market position. For instance, in 2021, Avantor launched a screening and process development buffer portfolio to accelerate drug development workflows.
Read More - https://www.insightprobing.com/biopharma-buffer-market-analysis-share-trend-demand-and-forecast/
Comments
Post a Comment